Key Insights• According to the research report, "China Inhalation Devices Market Outlook, 2031," published by Actual Market Research, the China Inhalation Devices Market was valued at more than 5.68 Billion in 2025.• The demand for inhalation devices in China is anchored by a massive chronic patient population alongside national health procurement integration. Epidemiological data from nationwide studies reveals that nearly 100 million adults in China live with Chronic Obstructive Pulmonary Disease (COPD), accounting for nearly 25% of all global COPD cases. Additionally, over 45 million Chinese citizens suffer from asthma. To expand therapeutic coverage across both urban tier-1 centers and tier-3/4 regional hospitals, the Chinese government has systematically incorporated core inhalation drug delivery systems such as pressurized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs) into the Volume-Based Procurement (VBP) policy.• A major technological breakthrough in China's respiratory market is the commercialization and local engineering of domestic multi-dose dry powder inhalers. Historically, the Chinese market relied heavily on imported, high-cost proprietary DPI platforms (such as Accuhaler or Turbuhaler) due to complex mechanical patents and precision mold manufacturing requirements. Chinese pharmaceutical and med-tech pioneers have successfully engineered domestic multi-dose DPI hardware that achieves precise micro-gram metering, uniform particle aerosolization, and stable moisture protection under humid climate conditions.• China is experiencing an accelerated integration of smart, connected inhalation devices paired with ubiquitous domestic digital platforms.

Addressing long-standing adherence challenges where proper inhalation technique is historically absent in over 60% of rural chronic patients manufacturers are embedding low-cost Bluetooth chips, breath-actuated acoustic sensors, and digital dose counters into handheld inhalation hardware. These smart modules sync seamlessly with mini-programs on WeChat and provincial hospital telehealth interfaces.Market Outlook• Under the Healthy China 2030 planning framework, the National Health Commission is expanding early screening initiatives, such as mandatory routine spirometry testing for high-risk populations aged 40 and older. This public health push is shifting routine asthma and COPD management from overburdened top-tier Class 3A hospitals to local community clinics, driving sustained volume adoption of compact, portable vibrating mesh nebulizers, single-dose DPIs, and breath-actuated inhalers across semi-urban and rural territories.• Key professional organizations and regulatory bodies shaping clinical protocols include the Chinese Thoracic Society (CTS), the Chinese Medical Association (CMA), and the National Medical Products Administration (NMPA). The competitive commercial landscape features leading domestic drug delivery innovators alongside major international pharmaceutical and medical technology providers, such as Sino Pharmactical, Jiangsu Hengrui Pharmaceuticals, AstraZeneca China, Sino-American Shanghai Squibb, Chiesi China, Vectura, GlaxoSmithKline (GSK) China, and Omron Healthcare China.Market DynamicsDriver: Massive chronic disease burden and expansion of primary healthcare screeningThe dominant catalyst driving the Chinese inhalation devices market is the immense, expanding baseline of chronic respiratory diseases, supported by government-led primary care screening initiatives. China accounts for approximately 100 million adults living with Chronic Obstructive Pulmonary Disease (COPD) and over 45 million people suffering from asthma. Driven by historical air quality challenges, high smoking rates among men, and an rapidly aging population, respiratory health has become a tier-1 public health priority.Challenge: Volume-based procurement (VBP) price compression and intellectual property barriersA primary challenge facing both domestic and foreign inhalation device manufacturers in China is the intense pricing pressure exerted by the National Volume-Based Procurement (VBP) policy, alongside complex drug-device intellectual property landscapes.

Under VBP tenders, winning suppliers secure bulk access to public hospital networks in exchange for drastic price cuts often exceeding 50% to 70% off original list prices. This severe margin compression restricts profit profitability and reduces capital available for long-term R&D. Furthermore, manufacturing high-precision, multi-dose dry powder inhalers requires advanced micro-engineering, specialized mold manufacturing, and complex aerosol particle formulation to ensure dose uniformity and moisture protection.Trend: Domestic import substitution and integration with digital health platformsA major structural trend reshaping the Chinese market is the rapid acceleration of domestic import substitution paired with WeChat-integrated digital healthcare ecosystems. Historically, top-tier (Class 3A) hospitals relied almost exclusively on imported, high-cost inhalation platforms. Encouraged by National Medical Products Administration (NMPA) fast-track approvals for locally developed combination products, domestic Chinese pharmaceutical and med-tech firms are rapidly capturing market share with high-quality, bioequivalent DPIs and vibrating mesh nebulizers.Segment Analysis China Inhalation Devices By Product Type• The China metered dose inhalers market is characterized by established clinical familiarity and growing interest in domestic development of inhalation formulations and device components. MDIs remain relevant for patients who need portable medication delivery, benefit from spacer compatibility, or cannot generate sufficient inspiratory effort for certain dry powder devices.

A distinctive market challenge is the technical integration of propellants, metering valves, actuators, and drug formulations, since small differences in component performance can affect dose consistency and aerosol delivery.• The China dry powder inhalers market is distinguished by its focus on powder formulation science, device resistance characteristics, and matching delivery systems to patients' inspiratory capabilities. DPIs avoid propellants and offer portable treatment, but their effectiveness depends on generating sufficient inspiratory force to disperse the medication and carry it into the lungs. Chinese clinical guidance emphasizes that capsule-based, reservoir, and blister-based devices have different preparation and operating requirements, making technique training essential.• The China soft mist inhalers market occupies a specialized position because these devices use mechanical energy to generate a slow-moving aerosol from a liquid formulation, rather than relying on conventional propellants or patient-powered powder dispersion. This delivery mechanism can reduce dependence on high inspiratory flow and may benefit selected patients who find coordination with traditional MDIs challenging. However, device operation can involve specific preparation, priming, and maintenance steps that require clear instruction.• The China nebulizers market is shaped by the use of aerosolized liquid medicines in hospital treatment, pediatric respiratory care, and selected home-care situations where handheld inhalers are unsuitable or a prescribed formulation requires nebulization. Product differentiation extends beyond aerosol generation to include noise levels, treatment duration, portability, cleaning requirements, and compatibility with prescribed solutions.

Compressor-based devices provide an established delivery option, while mesh technologies offer opportunities for compact designs and quieter operation. China Inhalation Devices By Therapeutic Application• The China asthma inhalation devices market is characterized by the need to improve long-term disease control through appropriate device selection, correct inhalation technique, and consistent use of prescribed medication. Device requirements vary across children, working-age adults, and older patients, making factors such as hand-breath coordination, inspiratory strength, and ease of preparation important. MDIs with spacers are relevant for patients who struggle with conventional actuation, while DPIs and SMIs provide alternatives for suitable individuals. A distinctive market opportunity lies in expanding standardized inhaler education through hospitals, community healthcare providers, and pharmacies, helping reduce errors that can compromise medication delivery.• The China COPD inhalation devices market is influenced by the long-term management of airflow limitation, the practical challenges of inhaler use among older adults, and the need to simplify maintenance treatment. Reduced inspiratory capacity, impaired hand coordination, and difficulties following multistep instructions can affect device suitability, making individualized assessment particularly important. Chinese clinical guidance emphasizes considering the patient's inspiratory flow, dexterity, and operating ability when choosing between MDIs, DPIs, SMIs, and nebulizers.• The others segment of the China inhalation devices market includes applications beyond asthma and COPD, such as cystic fibrosis, bronchiectasis, selected respiratory infections, and specialized pulmonary conditions requiring particular inhaled therapies.

These applications can require specific formulations, precise aerosol characteristics, and more complex treatment routines than conventional maintenance inhalers. Nebulizers are relevant for compatible liquid medications, including selected inhaled antibiotics and saline solutions, while specialized handheld systems may be suitable for particular therapies. An important market opportunity is the integration of domestic drug development with device engineering, allowing manufacturers to design delivery systems around the properties of specific formulations.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Inhalation Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product Type• Metered Dose Inhalers (MDIs)• Dry Powder Inhalers (DPIs)• Soft Mist Inhalers (SMIs)• NebulizersBy Therapeutic Application• Asthma• COPD• Others.